Is JAMA a Good Journal in 2026? An Honest Assessment

JAMA has an impact factor of 55.0 and rejects more than 95% of submissions. It receives more than 6,000 manuscripts per year. Most researchers know it as one of the four major general medical journals. What fewer researchers appreciate is that JAMA has a distinct editorial identity that makes it different from NEJM and The Lancet in ways that matter for targeting.

What Makes JAMA Different

JAMA publishes what might be called the full ecosystem of clinical medicine: original investigations, systematic reviews, meta-analyses, health services research, clinical guidelines, and practice-facing commentary. That breadth is deliberate.

NEJM is primarily a trial journal. The Lancet emphasizes global health and policy. JAMA covers more of the clinical medicine spectrum, including health systems, implementation, and comparative effectiveness alongside traditional clinical research.

That means the question of whether your paper fits JAMA isn't only about study design quality. It's about whether the clinical question and the finding are relevant to the broad physician readership of general internal medicine.

The IF of 55.0 in Context

JAMA's IF of 55.0 puts it fourth among the four major general medical journals, but its acceptance rate is among the lowest at less than 5%. The IF gap with NEJM (113 points) is wide; the editorial selectivity gap is not.

JAMA is the flagship of a large journal network: 13 JAMA Network journals cover every major specialty, from JAMA Cardiology and JAMA Oncology to JAMA Psychiatry and JAMA Network Open. Understanding that hierarchy matters before you choose where to submit.

The JAMA Network: Know Where Your Paper Fits

The flagship JAMA covers general internal medicine. The specialty journals cover their respective fields at high quality.

JAMA Oncology (IF 20.1): One of the top oncology journals. For oncology research, often a better first target than flagship JAMA unless the finding has general medicine significance.

JAMA Cardiology (IF 14.1): Leading cardiovascular medicine journal. Same logic applies.

JAMA Neurology, JAMA Internal Medicine, JAMA Psychiatry, JAMA Surgery, JAMA Pediatrics: All strong specialty journals with meaningful IFs. A strong paper in a specific domain often belongs at the specialty journal before the flagship.

JAMA Network Open (IF 9.7): Open access, higher acceptance rate, broader scope. Not a consolation prize for rejected flagship papers, but a legitimately different venue with different editorial expectations.

What JAMA Editors Screen For

Two criteria work together at triage: clinical significance and methodological rigor. Both have to be evident. A methodologically clean paper without broad clinical significance gets rejected. A clinically interesting question with weak methods gets rejected.

JAMA is particularly strong on clinical epidemiology. They care about study design clarity, appropriate statistical approach, reporting adherence (CONSORT for trials, STROBE for observational work, PRISMA for reviews), and honest characterization of limitations.

Editors also look for topical relevance. Papers that address currently active clinical questions, high-burden conditions, or debates where evidence is needed tend to do better than well-executed work on questions the field has already moved on from.

What Gets Desk Rejected Fast

The most common fast-rejection patterns:

General medicine relevance is unclear. A strong study in one subspecialty without connecting the findings to broader clinical practice. Subspecialty-specific work belongs at the JAMA specialty titles.

Methodological issues obvious at triage. Underpowered studies, post-hoc primary endpoints, or analysis plans that weren't prespecified for trials.

Clinical significance is small or incremental. JAMA needs findings that inform real clinical decisions. A statistically significant difference that doesn't move clinical practice is hard to place here.

Duplicate research. If several recent papers have addressed the same question, your study needs to add something new to the evidence base, not just replicate with a different cohort.

JAMA vs NEJM vs The Lancet

The overlap between these journals is real, and the choice matters.

NEJM: The landmark trial journal. Multicenter, practice-changing RCTs. The highest brand value in US academic medicine for clinical research.

The Lancet: Broader than NEJM, stronger on global health, epidemiology, and health policy. Better choice when the finding crosses national systems or affects global burden.

JAMA: The broadest clinical scope. Health services, implementation, comparative effectiveness, systematic reviews alongside traditional RCTs. Best when the paper's contribution is rigorous clinical evidence that doesn't need the narrow landmark framing of NEJM.

If your paper is a major multicenter trial: NEJM or Lancet first. If it's a rigorous clinical study with important but not landmark implications: JAMA is the right target.

The Submission Process at JAMA

JAMA uses Editorial Manager. Key specifics:

Word limits. Original Investigation: 3,500 words (text only, not including abstract, tables, figures, or references). Structured abstract: 350 words with required headers (Importance, Objective, Design/Setting/Participants, Exposure/Interventions, Main Outcomes, Results, Conclusions). Research Letter: 600 words, 1 table or figure, 6 references.

Manuscript components. Title page (with key points), structured abstract, manuscript text, tables and figures, statistical methods, and supplementary materials. Missing components cause submission to bounce back.

ICMJE requirements. JAMA is an ICMJE member journal and follows ICMJE recommendations on authorship, conflict of interest disclosure, and clinical trial registration strictly. Every author must complete a conflict of interest disclosure form.

Open access option. JAMA offers open access publication at an APC of approximately $5,000. Most institutional agreements with AMA cover some or all of this.

How JAMA Handles Statistical Review

JAMA has a dedicated biostatistical review team. For complex analyses, your paper may be reviewed both by clinical content experts and by a biostatistician. This means statistical issues that would survive peer review at many journals get caught at JAMA.

Common statistical flags that JAMA reviewers raise:

• Post-hoc primary endpoint changes without documentation of pre-specification
• Missing confidence intervals for primary endpoints
• Inadequate power calculations or retrospective power calculations
• Multiple comparisons not addressed in analysis plan
• Inappropriate use of p-values as a dichotomous pass/fail threshold

Prespecifying your analysis plan and registering it's the cleanest way to preempt these concerns.

JAMA vs Its Network Journals: The Realistic Routing Decision

A paper that gets desk rejected from JAMA flagship sometimes gets fast-tracked at a JAMA Network specialty journal. The editorial teams are independent, but JAMA editors sometimes recommend transfer.

JAMA Network Open is the open-access journal with a broader acceptance scope. Papers that are methodologically sound and clinically relevant but fall below flagship significance often find a home there.

The JAMA Network journals are not consolation prizes. JAMA Cardiology and JAMA Oncology are top-five journals in their respective fields. Routing to the right specialty title is often a better strategic outcome than spending multiple cycles on the flagship.

What Improves Acceptance Odds

JAMA rewards clarity and restraint. Papers that overclaim get punished. Papers that present effect size, limitations, and practical implication clearly tend to do better.

Quick Routing Heuristic

If your strongest contribution is specialty-specific, route to the matching JAMA Network journal first. If your question affects broad general medicine decisions, flagship JAMA is justified.

Final Decision Rule

If your manuscript can answer a broad clinician's "what do I do differently tomorrow?" question with evidence, JAMA is a valid first target. If it can only answer a specialty-method question, route to the matching network journal.

That one call usually determines timeline.

Execution Note

A concise abstract and disciplined cover letter often improve triage outcomes more than adding extra narrative to discussion sections.

Final Fit Signal

If the study answers a broad clinical question with actionable evidence, JAMA is a valid first shot.

Implementation Checklist

Before submission, confirm three basics: claim clarity, methodological transparency, and journal-specific framing. Most avoidable rejections happen because one of these is weak in the first page.

Treat this as a production checklist, not an optional polish step. Small execution fixes often change editorial outcomes.

The Bottom Line

JAMA is a legitimate top-four medical journal with a specific strength in methodological rigor and broad clinical scope. It's not a consolation prize for papers that didn't make it to NEJM. For health services research, comparative effectiveness, and rigorous studies that address high-burden clinical questions, JAMA is often the right first target.

Know the network hierarchy before submitting. A domain-specific paper often belongs at JAMA Oncology or JAMA Cardiology before it belongs at the flagship.

Sources

• JAMA instructions for authors: jamanetwork.com/journals/jama/pages/instructions-for-authors
• JAMA Network journals: jamanetwork.com
• Clarivate Journal Citation Reports 2025
• Full JAMA journal profile

See also

• Is NEJM a good journal?
• Is The Lancet a good journal?
• JAMA cover letter guide